Switch to:
More From Other Websites
Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma Nov 24 2014
Genmab to Present at the Jefferies 2014 Global Healthcare Conference Nov 14 2014
Report Pursuant to Section 28a of the Danish Securities Trading Act Nov 12 2014
Capital Increase in Genmab as a Result of Employee Warrant Exercise Nov 12 2014
Genmab's Financial Calendar for 2015 Nov 10 2014
Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma Nov 10 2014
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology... Nov 06 2014
Genmab Announces Financial Results for the First Nine Months of 2014 Nov 05 2014
Genmab Announces Conditional Transfer of Ofatumumab Agreement Nov 03 2014
Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen Oct 23 2014
Third Quarter 2014 Net Sales Figures for Arzerra® Oct 22 2014
Grant of Warrants to Genmab Employees Oct 15 2014
GENCOR INDUSTRIES INC Financials Aug 15 2014
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
A Letter To Gencor Industries' Board Of Directors May 23 2014
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 09 2014
GENCOR INDUSTRIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 14 2014
GENCOR INDUSTRIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 07 2014
GENCOR INDUSTRIES INC Files SEC form 10-Q, Quarterly Report Feb 07 2014
GENCOR RELEASES FISCAL YEAR AND FOURTH QUARTER 2013 RESULTS Dec 18 2013


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK